ERBB2 and breast cancer: If a molecular alteration in this gene is detected, on the basis of SOLAR-1 trial results [262], the FDA approves the administration of alpelisib, a PI3Kα inhibitor, in association with fulvestrant in advanced and metastatic HR+/HER2- BC.